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The mammalian myocardium is an omnivorous organ that relies on multiple substrates in order to fulfill its tremendous energy
demands. Cardiac energy metabolism preference is regulated at several critical points, including at the level of gene transcription.
Emerging evidence indicates that the nuclear receptor PPARα and its cardiac-enriched coactivator protein, PGC-1α, play important roles in the transcriptional control of myocardial energy metabolism. The PPARα-PGC-1α complex controls the expression of
genes encoding enzymes involved in cardiac fatty acid and glucose metabolism as well as mitochondrial biogenesis. Also, evidence
has emerged that the activity of the PPARα-PGC-1α complex is perturbed in several pathophysiologic conditions and that altered
activity of this pathway may play a role in cardiomyopathic remodeling. In this review, we detail the current understanding of the
eﬀects of the PPARα-PGC-1α axis in regulating mitochondrial energy metabolism and cardiac function in response to physiologic
and pathophysiologic stimuli.
Copyright © 2008 J. G. Duncan and B. N. Finck. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.

1.

INTRODUCTION

The myocardium has an enormous and steady demand for
energy that is met through high-level mitochondrial oxidative metabolism. Glucose, lactate, and fatty acids are all oxidized in the mitochondrion to produce reducing equivalents
required for ATP synthesis in the process of oxidative phosphorylation (OXPHOS). Much of the mitochondrial-derived
ATP is then transported to the cytoplasm, making energy
available for cellular work, which includes its crucial role in
cardiac myocyte contraction. Acute changes in flux through
these metabolic pathways are mediated by changes in substrate concentrations and covalent or allosteric modification
of enzymes catalyzing these reactions. However, the capacity
for mitochondrial oxidative metabolism is also mediated at
the level of gene transcription [1].
Work in several labs has demonstrated that the three
PPAR isoforms (PPARα, β/δ, and γ) are expressed, to varying
degrees, in the myocardium and play important roles in the
transcriptional regulation of cardiac metabolism and function. The ability to modulate PPAR activity with specific ac-

tivating ligands as well as genetic activation or deactivation
in mice has enriched our understanding of the importance
of each of the various PPAR isoforms in determining cardiac metabolism, structure, and function. However, given the
limited space available in this review, we will focus our attention on the PPARα isoform and its coactivator protein PGC1α.
2.

PPARα AND MYOCARDIAL
FATTY ACID METABOLISM

The PPARα isoform is robustly expressed in the parenchymal
cells of the adult heart and plays an important role in regulating cardiac myocyte metabolism [2, 3]. In the myocardium,
PPARα activation induces the expression of genes encoding
nearly every step in the cellular fatty acid utilization pathway
including (i) fatty acid transport proteins that facilitate fatty
acid entry into the cell, (ii) acyl-CoA synthetases that esterify
fatty acids to coenzyme A and prevent their eﬄux, (iii) fatty
acid binding proteins that shuttle fatty acids to various cellular compartments, (iv) proteins that catalyze the import of
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fatty acids into the mitochondrion, (v) every enzyme in the
mitochondrial fatty acid β-oxidation spiral, and (vi) various
accessory components of fatty acid metabolism (e.g., uncoupling proteins).
Administration of PPARα ligand to rodent models results in a robust activation of PPAR target genes in liver, but
the eﬀects of in vivo ligand administration on cardiac gene
expression is minimal [4]. Indeed, PPARα agonist administration to diabetic mice actually leads to diminished cardiac fatty acid utilization [5, 6], possibly by reducing the exposure of the heart to triglyceride-rich lipoproteins or endogenous fatty acid ligands. It is unclear whether PPARα
ligand administration targets the heart directly in humans;
and there are likely diﬀerences in the PPAR response between
the species. Due to the hepatic specific eﬀects of PPARα ligands in rodents, much of our knowledge regarding the target pathways of PPARα in myocardium is based on studies
with genetic alterations in PPARα activity. Mice with constitutive deletion (in all tissues) of the gene encoding PPARα
(PPARα null mice) exhibit diminished rates of cardiac fatty
acid oxidation (FAO) and increased reliance on glucose utilization pathways [7–9]. This shift is mediated, at least in
part, by diminished expression of several genes involved in
FAO [10] and a concomitant increase in the expression of
genes encoding proteins involved in glucose uptake and utilization [7]. At the other end of the metabolic spectrum, we
have characterized transgenic mice overexpressing PPARα in
a cardiac-restricted manner (MHC-PPARα mice) [8, 11–16].
The expression of many genes involved in fatty acid uptake
and utilization is upregulated in MHC-PPARα mice, while
the expression of glucose transporter and glycolytic enzymes
is strikingly suppressed [11]. Consistent with this pattern of
metabolic gene expression, MHC-PPARα mice rely almost
exclusively on FAO and use very little glucose [8, 9, 11]. In
summary, the opposing metabolic phenotypes of these transgenic models with activation or deactivation of PPARα support an important role for PPARα in regulating cardiac energy metabolism.
3.

THE PGC-1α TRANSCRIPTIONAL
COACTIVATOR AND THE CONTROL OF
CARDIAC ENERGY METABOLISM

Transcriptional coactivators are a group of proteins that
control gene expression via protein-protein interactions
with DNA-bound transcription factors, including PPARα
(Figure 1). Although several transcriptional coactivators are
known to interact with PPARα, in the heart, the physical and
functional interaction with PPARγ coactivator 1α (PGC-1α)
has been best described. PGC-1α was originally discovered in
a yeast two-hybrid screen for proteins that interacted with the
PPARγ isoform and that were enriched in a brown adipocyte
library [17]. Based on sequence homology in some highly
conserved regions, two additional PGC-1 family members
have now been identified (PGC-1β and PGC-related coactivator (PRC)) [18, 19].
Coactivators are broadly categorized into two classes.
Class I coactivators regulate genetranscription through en-

zymatic modification of chromatin (e.g., acetylation and
methylation), which facilitates DNA unwinding and enhances the probability that a gene will be transcribed by the
RNA polymerase II complex. Class II coactivators work by
interacting with the RNA polymerase machinery (e.g., RNA
polymerase II or the TRAP/DRIP complex) [20, 21]. PGC1α functions as a Class II coactivator since it does not possess
intrinsic chromatin modifying activity and interacts directly
with the TRAP/DRIP complex to link with RNA polymerase
II (Figure 1) [20]. PGC-1α also recruits Class I coactivators
with histone acetyltransferase activity to chromatin in the
target gene promoter [20, 22] and docks with a protein called
ménage-à-trois 1, which phosphorylates RNA polymerase II
to modulate its activity (Figure 1) [23]. Finally, PGC-1α possesses an RNA processing domain that may also contribute
to its transcriptional regulatory function [24].
PGC-1 interacts with and coactivates a broad array
of transcription factors to transduce developmental, nutritional, and physiological stimuli to the control of diverse cellular energy metabolic pathways [25, 26]. In heart, PGC-1α
has thus far been linked with 3 families of transcription factors: (i) the PPAR family, (ii) the estrogen-related receptor
(ERR) family, and (iii) nuclear respiratory factor 1 (NRF1). The interaction between PGC-1α and PPARα serves to
control the expression of enzymes involved in fatty acid uptake and oxidation [27] and possibly proteins involved in the
process of mitochondrial biogenesis [15]. The ERR family
(ERRα, β, γ) of orphan nuclear receptors is also an important cardiac PGC-1α target that drives increased expression
of genes encoding FAO and OXPHOS enzymes [28–31]. Finally, NRF-1 is a nuclear-encoded transcription factor that
is coactivated by PGC-1α to regulate transcription of genes
involved in mitochondrial OXPHOS, mtDNA transcription
and replication, and mitochondrial biogenesis [32–35]. Additional details regarding PGC-1-mediated control of energy
metabolism through ERRα and NRF-1 can be found in other
recent reviews [26, 35–37].
Several genetically-engineered mouse models have been
used to probe the role of PGC-1α in regulating cardiac
metabolism. Mice that constitutively overexpress PGC-1α in
the myocardium exhibit profound mitochondrial proliferation, cardiomyopathy, and early death secondary to heart
failure [33]. The severity of the cardiomyopathy in this model
precluded a full investigation of the pathologic mechanisms
that contribute to cardiac dysfunction. To address this issue,
a second model evaluated overexpression of PGC-1α in the
heart using a tetracycline-inducible system [38]. This model
revealed dramatic mitochondrial proliferation when PGC1α was overexpressed in the neonatal phase, without overt
eﬀects on cardiac function. In contrast, overexpression of
PGC-1α in adult mice provoked only modest mitochondrial
proliferation, but led to abnormal mitochondrial and myofibril architecture and severe cardiac dysfunction [38]. Interestingly, cardiomyopathy in these mice was completely reversible by discontinuing PGC-1α overexpression [38]. These
gain-of-function strategies indicate that PGC-1α plays important roles in regulating multiple aspects of myocardial
metabolism and is a strong stimulus for the process of mitochondrial biogenesis.
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Figure 1: Mechanisms of PPARα activation and PGC-1α coactivator activity. Depiction of a potential PPARα target gene and nuclear receptor
response element (NRRE) within the promoter region in the nonactivated state (top). PPARα activation by fatty acid (FA) ligand leads to
binding to the NRRE with its heterodimeric partner RXRα; and its coactivator PGC-1α. PGC-1α recruits additional coactivators with histone
acetyltransferase (HAT) activity, which promotes chromatin unwinding and increases RNA polymerase II (POL II) access to the target gene
promoter (middle). PGC-1α also interacts with the TRAP/DRIP complex and with ménage-à-trois 1 (MAT1) which phosphorylates POL
II to increase the probability of gene transcription. In addition, PGC-1α plays a role in RNA splicing via an RNA processing domain in its
C-terminus (bottom).

The cardiac phenotype of two separate lines of mice
with constitutive PGC-1α deficiency also support an important role for PGC-1α in cardiac metabolism and function
[39–41]. Both lines of PGC-1α-deficient mice exhibit impaired mitochondrial OXPHOS function and decreased expression of many genes encoding enzymes in mitochondrial
metabolic pathways. PGC-1α deficiency also leads to cardiac
dysfunction, especially in the context of pathophysiologic
stimuli like pressure overload-induced cardiac hypertrophy
[40, 41]. Interestingly, the severity of the cardiac functional
phenotype varies between the two lines of knockout mice.
One line exhibits age-associated cardiac dysfunction that is
manifested by 7-8 months old as left ventricular chamber
dilatation, diminished fractional shortening, and an activation of gene markers of cardiomyopathy [41]. Conversely, the
other line of knockout mice exhibits no signs of cardiac dys-

function, but displays diminished chronotropic capacity in
response to a β-adrenergic stimulus [39]. The mechanistic
basis for this disparity in the two mouse mouse models is unknown. Collectively, these gain- and loss-of-function studies
demonstrate that PGC-1α has a critical role in control of cardiac energy metabolism.
4.

PPARα-PGC-1α-MEDIATED CONTROL OF
METABOLISM IN RESPONSE TO
DEVELOPMENTAL OR PHYSIOLOGIC CUES

Myocardial energy substrate preference is remarkably pliant and the heart can rapidly modulate fuel utilization depending upon the developmental stage, nutritional context,
or disease state [42]. The PPARα-PGC-1α complex plays
an important role in catalyzing these changes. For example,
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Figure 2: Dynamic regulation of PPARα-PGC-1α complex activity in developing, failing, and diabetic heart. Physiological cardiac growth
resulting from postnatal maturation is associated with increased PPARα and PGC-1α expression and marked expansion of mitochondrial
volume density and oxidative capacity. Conversely, pathologic hypertrophy is linked to decreased PPARα-PGC-1α expression and/or activity
and diminished reliance on oxidative mitochondrial metabolism often leading to intramyocellular lipid accumulation. Finally, in the diabetic
heart, PPARα-PGC-1α complex activity is increased along with the cardiac reliance on FAO. Despite of high-level FAO, the cardiac lipid
accumulation is a hallmark of the diabetic heart and lipotoxicity may play a key role in the development of diabetic cardiomyopathy.

the fetal heart utilizes predominantly anaerobic glucose
metabolism to fulfill its energy needs. However, almost immediately after birth, a rapid and profound developmental
shift occurs. The workload of the heart is increased and the
availability of fatty acids and oxygen for fuel becomes much
greater (Figure 2). In response to these changes, the myocardium increases its reliance on mitochondrially derived
ATP as an energy source through a coordinated induction
of mitochondrially and nuclear-encoded genes involved in
mitochondrial metabolism, structure, and function [43–45].
This developmental shift is accompanied by a robust activation of the PPARα-PGC-1α system [33, 43]; and it is likely
that these two factors play a crucial role in this developmental switch.
Fasting is another physiologic context associated with a
marked increase in PPARα-PGC-1α activity. To “spare” glucose for other organs that lack the capacity to catabolize fatty
acids, the heart markedly increases its use of fatty acids under

conditions of food deprivation [42]. Although the expression
of the gene encoding PPARα is unaltered, the expression of
PGC-1α is strongly induced [33]. Together with heightened
availability of fatty acids that act as endogenous ligands for
PPARα, this serves to rapidly amplify PPARα transcriptional
activity. In fact, the expression of the broad program of myocardial FAO enzymes is markedly induced by food deprivation and this response is significantly blunted in mice lacking
PPARα [10]. In sum, the PPARα-PGC-1α complex serves to
regulate the capacity for FAO in response to physiologic cues
that signal an increased need for mitochondrial fatty acid utilization.
5.

ALTERED PPARα-PGC-1α SIGNALING
IN THE FAILING HEART

Cardiac energy substrate metabolism is perturbed in the
hypertrophied and failing heart, reverting to a program of
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energy substrate metabolism similar to the “fetal” profile
(Figure 2). Specifically, the myocardium shifts from dependence on FAO towards glucose utilization; primarily anaerobic glycolysis [46–49]. Importantly, this switch in energy
substrate preference detected in various experimental models is also observed in humans with idiopathic dilated cardiomyopathy [50]. These changes in energy substrate preference are mediated, at least in part, by a downregulation of the genes encoding enzymes involved in FAO, OXPHOS, and the PPARα-PGC-1α complex [3, 48, 51–60].
The expression of the genes encoding PPARα and PGC1α is known to be diminished in several rodent models of
pressure overload or hypertensive heart disease [3, 40, 61],
pacing-induced heart failure [62, 63], hypoxia [52], ischemic
heart disease [55, 58, 59, 64], as well as genetically engineered models of heart failure [65–67]. The molecular mechanisms whereby pathologic stimuli lead to a transcriptional
downregulation of PPARα and PGC-1α are not well understood, but may involve reactive oxygen species generation
[64]. In addition, under pathologic conditions, PPARα activity is inhibited post-translationally through lower levels
of the obligate heterodimeric partner of PPARα, retinoid X
receptor (RXR) [57], and direct phosphorylation by the extracellular signal-related kinase and mitogen-activated protein kinase (ERK-MAPK) pathway [3]. These findings suggest that deactivation of the cardiac PPARα-PGC-1α axis
in failing heart is a key component of the observed shift
in energy metabolism. In support of this, reactivation of
PPARα or PGC-1α prevents the downregulation of oxidative gene expression that occurs in cardiac myocytes challenged with pathologic stimuli [61, 63–65, 68, 69]. Experimental models have found altered metabolism and gene expression in both the hypertrophied and the overtly failing
heart, but longitudinal evaluation of progressive changes in
the PPARα-PGC-1α axis has not been done. Studies to evaluate the sequence of events will be crucial to understanding
the role of altered metabolic regulation in disease progression.
One point that remains to be addressed is whether deactivation of oxidative metabolism and the PPARα-PGC-1α
complex in the hypertrophied and failing heart is adaptive
or maladaptive. The shift towards glycolysis allows continued ATP production with less oxygen consumption, and thus
would appear to be an adaptive response. Indeed, overexpression of the GLUT1 glucose transporter prevented cardiac
dysfunction in response to pressure overload [70]. Partial inhibitors of FAO also produce positive inotropic eﬀects in patients with ischemic and nonischemic heart disease [71–76].
Ligand-mediated activation of PPARα in models of pressure
overload [61] or ischemia [64] exacerbated ventricular dysfunction and pathologic remodeling. However, other reports
show no ill eﬀects of PPARα agonism or increased FAO in
pathologic conditions [68, 69, 77]. Moreover, there is abundant evidence that chronic shifts towards glycolysis are maladaptive. Most reports suggest that PPARα agonists are beneficial in the response to ischemia [78–80] and various models of heart failure [63, 81–83]. Similarly, PGC-1α overexpression rescued the cardiac myocyte dysfunction and apoptosis in a mouse model of cardiomyopathy [65]. Mice with
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chronic reliance on glucose metabolism due to loss of cardiac
lipoprotein lipase develop cardiac dysfunction with age and
demonstrate significant mortality associated with the stress
of aortic banding [84]. Finally, PPARα deficient animals that
shift metabolism predominantly towards glucose oxidation
exhibit age-associated cardiac fibrosis [85] and were unable
to respond to increased workload and developed energy depletion [86].
The concept that the myocardium must maintain
metabolic flexibility and a balance of substrate utilization
during pathologic remodeling has recently pushed to the
forefront. However, the biologic basis for this concept is unclear. It may be that chronic reliance on glucose as the predominant substrate is insuﬃcient for ATP production in failing heart. Compared to FAO, glycolysis produces much less
ATP per mole of substrate and there is evidence that longterm reliance on glycolysis leads to ATP deficiency in failing
heart. Indeed, the phospho-creatine/ATP ratio is reduced in
failing heart [49, 87–89] and a decline in this ratio is predictive of impending mortality in human heart failure patients [90]. The idea that energy starvation plays a significant
role in the development of heart failure is also supported by
severe cardiomyopathies in animal models with deletions in
FAO enzymes [91, 92] or enzymes involved in mitochondrial
ATP production [93–95]. Moreover, humans with inborn errors in these pathways often present with cardiomyopathy
[96]. It is also possible that impairments in rates of FAO in
failing heart are maladaptive because they lead to myocardial
lipid accumulation (lipotoxicity) [97], which is linked to cardiac dysfunction [98–100]. Alternatively, or in addition, the
inability to switch energy substrate preference in the context
of changes in substrate availability could also contribute to
pathologic remodeling.
6.

PPARα AND PGC-1α IN THE DIABETIC HEART

Cardiovascular disease is exceptionally prevalent in patients
with diabetes. Although the prevalence of dyslipidemias and
hypertension certainly contributes to cardiovascular risk in
diabetic subjects, cardiomyopathy is highly prevalent independent of these risk factors. Cardiomyopathy in diabetic
subjects that occurs in the absence of known risk factors is
often termed “diabetic cardiomyopathy” [101–104]. Unfortunately, the etiology of diabetic cardiomyopathy is poorly
understood.
Evidence has emerged that abnormalities in myocardial
energy metabolism play a significant role in the pathogenesis
of diabetic cardiomyopathy. Indeed, in experimental models
of uncontrolled diabetes (type 1 or 2), cardiac energy substrate flexibility becomes constrained and the diabetic heart
relies almost exclusively on mitochondrial FAO for its ATP
requirements [105–108]. Recently, these metabolic observations from animal models have also been confirmed in human subjects with type 1 diabetes [109]. The expression of
PPARα, PGC-1α, and many target genes involved in FAO
are increased in the murine insulin-resistant [15] and diabetic heart (type 1 and type 2) [11, 110, 111] and may
play a key role in the observed metabolic switch to FAO.
PPARα deficiency in the setting of insulin resistance [15] or
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diabetes [110] blunts activation of FAO gene expression, suggesting that activation of the PPARα-PGC-1α regulatory network is critical for the increased FAO rates and lipid uptake
seen in the diabetic heart. Consistent with this, transgenic
mice that overexpress PPARα exclusively in the heart (MHCPPARα mice) have a cardiac metabolic phenotype similar to
that observed in diabetic heart, including accelerated rates
of FAO, a striking diminution in glucose uptake and utilization, and a mitochondrial biogenic response [11, 15]. We
have also observed that high-level fatty acid utilization in
hearts of MHC-PPARα mice leads to the development of
cardiac hypertrophy and dysfunction [11, 12]. We believe
that sustained activation of the PPARα-PGC-1α complex in
the insulin-resistant and diabetic heart promotes a state of
metabolic inflexibility that leads to cardiomyopathic remodeling.
Despite high rates of FAO, myocardial lipid accumulation is a hallmark of the diabetic heart [112–116]. Prolonged
accumulation of fats in the myocardium is believed to be
highly toxic and is linked to the development of insulin resistance and cardiac dysfunction [12, 98–100, 114]. Our data
suggest that PPARα drives this lipotoxic response in diabetic
heart. The cardiomyopathic phenotype is relatively mild in
unchallenged MHC-PPARα mice, but when the transgenic
mice were given a high-fat diet, the cardiomyopathic phenotype was strikingly exacerbated; and mice exhibited clinical
signs of heart failure, including depressed fractional shortening and ventricular chamber dilatation [12]. Pathologic remodeling in MHC-PPARα mice was accompanied by marked
cardiac lipid accumulation. Moreover, genetic ablation of the
fatty acid transporter CD36 in the context of PPARα overexpression prevents high-fat diet-induced cardiac lipid accumulation and dysfunction [16]. Finally, ligand-mediated activation of PPARα also drives lipid accumulation and an adverse outcome following ischemic insult [64]. These findings
suggest that PPARα-driven lipotoxicity could be an important mechanism in cardiomyopathic remodeling of the diabetic heart.
Other components of the metabolic derangements in diabetic heart are abnormalities in mitochondrial ultrastructure and function [15, 111, 117–120]. Mitochondria isolated from diabetic rodents exhibit depressed rates of OXPHOS [117, 118] and diminished eﬃciency in ATP synthesis [120, 121], likely due to increased uncoupled respiration
[121]. Mitochondrial proliferation is common in hearts of
diabetic rodents [15, 119, 121, 122]. However, mitochondria
from both type 1 and type 2 diabetic hearts often exhibit
ultrastructural abnormalities, including degenerative cristae
[15, 119]. The literature regarding the eﬀects of insulin resistance and diabetes on mitochondrial gene expression is
mixed with some reports showing an activation [15, 119] and
others showing deactivation [123, 124]. We recently found
that mitochondrial biogenesis and OXPHOS gene expression
are increased in a mouse model of obesity-related insulin resistance [15]. These eﬀects of insulin resistance were blunted
in PPARα null mice and recapitulated in MHC-PPARα mice,
suggesting that PPARα is involved in mitochondrial biogenesis in the myocardium in the context of insulin resistance,
which was previously not well-appreciated.
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7.

CONCLUSIONS

In summary, the heart requires a continuous and abundant
source of substrate to meet it high-energy demands. In situations where energy needs change, such as heart failure, the
heart must adapt and will utilize the most eﬃcient source of
substrate (glucose) to meet its needs. Similarly, when glucose
availability becomes limited, as it does in fasting or diabetes,
the heart will adapt and use fatty acid to meet its ATP requirements. PPARα and PGC-1α play a central role in this
metabolic flexibility by driving robust changes in gene expression of key components of mitochondrial biogenesis and
metabolism. However, it is still not entirely clear whether
long-term PPARα-PGC-1α-mediated alterations in energy
metabolism are adaptive versus maladaptive changes for both
heart failure and diabetic cardiomyopathy.
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[63] F. Brigadeau, P. Gelé, M. Wibaux, et al., “The PPARα activator
fenofibrate slows down the progression of the left ventricular
dysfunction in porcine tachycardia-induced cardiomyopathy,” Journal of Cardiovascular Pharmacology, vol. 49, no. 6,
pp. 408–415, 2007.
[64] O. Dewald, S. Sharma, J. Adrogue, et al., “Downregulation of
peroxisome proliferator-activated receptor-α gene expression
in a mouse model of ischemic cardiomyopathy is dependent
on reactive oxygen species and prevents lipotoxicity,” Circulation, vol. 112, no. 3, pp. 407–415, 2005.
[65] M. Sano, S. C. Wang, M. Shirai, et al., “Activation of cardiac
Cdk9 represses PGC-1 and confers a predisposition to heart
failure,” EMBO Journal, vol. 23, no. 17, pp. 3559–3569, 2004.
[66] K. Sekiguchi, Q. Tian, M. Ishiyama, et al., “Inhibition of
PPAR-α activity in mice with cardiac-restricted expression
of tumor necrosis factor: potential role of TGF-β/Smad3,”
American Journal of Physiology, vol. 292, no. 3, pp. H1443–
H1451, 2007.
[67] C. Pellieux, E. Aasum, T. S. Larsen, et al., “Overexpression of
angiotensinogen in the myocardium induces downregulation
of the fatty acid oxidation pathway,” Journal of Molecular and
Cellular Cardiology, vol. 41, no. 3, pp. 459–466, 2006.

J. G. Duncan and B. N. Finck
[68] E. E. Morgan, J. H. Rennison, M. E. Young, et al., “Eﬀects
of chronic activation of peroxisome proliferator-activated
receptor-α or high-fat feeding in a rat infarct model of heart
failure,” American Journal of Physiology, vol. 290, no. 5, pp.
H1899–H1904, 2006.
[69] V. Labinskyy, M. Bellomo, M. P. Chandler, et al., “Chronic activation of peroxisome proliferator-activated receptor-α with
fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in
pacing-induced heart failure,” Journal of Pharmacology and
Experimental Therapeutics, vol. 321, no. 1, pp. 165–171, 2007.
[70] R. Liao, M. Jain, L. Cui, et al., “Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice,” Circulation, vol. 106,
no. 16, pp. 2125–2131, 2002.
[71] H. N. Sabbah, M. P. Chandler, T. Mishima, et al., “Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart
failure,” Journal of Cardiac Failure, vol. 8, no. 6, pp. 416–422,
2002.
[72] H. N. Sabbaha and W. C. Stanley, “Partial fatty acid oxidation
inhibitors: a potentially new class of drugs for heart failure,”
European Journal of Heart Failure, vol. 4, no. 1, pp. 3–6, 2002.
[73] M. P. Chandler, P. N. Chavez, T. A. McElfresh, H. Huang, C.
S. Harmon, and W. C. Stanley, “Partial inhibition of fatty acid
oxidation increases regional contractile power and eﬃciency
during demand-induced ischemia,” Cardiovascular Research,
vol. 59, no. 1, pp. 143–151, 2003.
[74] W. C. Stanley and M. Marzilli, “Metabolic therapy in the
treatment of ischaemic heart disease: the pharmacology
of trimetazidine,” Fundamental and Clinical Pharmacology,
vol. 17, no. 2, pp. 133–145, 2003.
[75] H. Rupp, A. Zarain-Herzberg, and B. Maisch, “The use of
partial fatty acid oxidation inhibitors for metabolic therapy
of angina pectoris and heart failure,” Herz, vol. 27, no. 7, pp.
621–636, 2002.
[76] A. Zarain-Herzberg and H. Rupp, “Therapeutic potential of
CPT I inhibitors: cardiac gene transcription as a target,” Expert Opinion on Investigational Drugs, vol. 11, no. 3, pp. 345–
356, 2002.
[77] W. C. Stanley, E. E. Morgan, M. P. Chandler, and B. D. Hoit,
“Up-regulation of the fatty acid oxidation (FAO) pathway
does not exacerbate heart failure in rats,” Cardiovascular Journal of South Africa, vol. 15, pp. S6–S7, 2004.
[78] N. S. Wayman, B. L. Ellis, and C. Thiemermann, “Ligands
of the peroxisome proliferator-activated receptor-PPAR-α reduce myocardial infarct size,” Medical Science Monitor, vol. 8,
no. 7, pp. BR243–BR247, 2002.
[79] T.-L. Yue, W. Bao, B. M. Jucker, et al., “Activation of peroxisome proliferator-activated receptor-α protects the heart
from ischemia/reperfusion injury,” Circulation, vol. 108,
no. 19, pp. 2393–2399, 2003.
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